R.E.D. Institut fuer medizinische Studien und Fortbildung GmbH — Clinical Trial Site

43 Registered trials

13 Currently recruiting

Organisation

R.E.D. Institut fuer medizinische Studien und Fortbildung GmbH

Location

Oldenburg In Holstein, Germany

Identifier

ORG-100040953

Address

Markt 15, 23758, Germany

Departments

-
DE018
Diabetes/Cardiovascular Disease
Geschaeftsfuehrung
Institut
Institut für Med. Forschung und Fortbildung Innere Medizin/Diabetologie
internal medicine, diabetology
N/A
NA
Praxis für Gastroenterologie, Kronsforder Allee 69, 23560 Lübeck
private practice
R.E.D. Institut
R.E.D. Institut fuer medizinische Studien und Fortbildung GmbH
RED Institut
RED-Institut
RED-Institut GmbH

Clinical trials at this site (43)

Search interface

OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Pending

2025-523486-17-00 Obesity 5
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending

2025-523510-87-00 Obesity 5
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ENLIGHTEN-3) Recruiting

2025-523769-11-00 Overweight 5 2026-04-30
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRES… Recruiting

2025-522170-36-00 Diabetes Mellitus, Type 1 5 2026-02-03
A Study of Tirzepatide Compared with Intensified Conventional Care in Adult Participants with Type 2 Diabetes (SURPASS-EARLY) Recruiting

2022-501073-40-00 Type 2 Diabetes 6 2023-01-27
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D… Recruiting

2025-523123-22-00 Chronic Kidney Disease 5 2026-05-07
AMAZE 12: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight maintain their weight loss Recruiting

2025-523804-62-00 Obesity 5 2026-04-28
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes ( ENLIGHTEN-1). Recruiting

2025-523657-34-00 Obesity 5 2026-04-13
A Study of Eloralintide (LY3841136) in Participants with Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2) Recruiting

2025-523658-15-00 Obesity 5 2026-04-10
Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-… Recruiting

2025-522703-14-00 "Moderate to severe obstructive sleep apnea (OSA) in ad 5 2026-02-17
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Study of LY3457263 Compared to Placebo in Participants with Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide Recruiting

2024-520328-27-00 Type 2 Diabetes 4 2025-08-07
Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy… Recruiting

2022-500531-36-00 Type 1 diabetes mellitus 4 2024-02-02
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
Weight loss in people living with overweight or obesity following treatment with cagrilintide Ended

2024-519530-24-00 Overweight and obesity 5 2025-10-31
J2A-MC-GZPO: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes J2… Ended

2025-521098-14-00 GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes 5 2025-08-15
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening);… Ended

2024-519000-27-00 Hypertension 5 2025-07-17
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARIT… Ended

2024-515523-11-00 Chronic Weight Management 5 2025-06-09
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA… Ended

2024-515524-36-00 Chronic Weight Management 5 2025-05-30
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA) Ended

2024-515905-25-00 Overweight or Obesity 5 2025-01-29
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn… Ended

2023-506457-38-00 Chronic kidney disease (CKD) and hypertension. 5 2024-06-05